Why Agenus Inc. Stock Slumped Today
Shares of the cancer immunotherapy and vaccine company Agenus (NASDAQ: AGEN) fell by as much as 16.7% on nearly five times the average volume today, before ultimately ending the day down by only 5.1%. This sizable move lower was triggered by a $250 million mixed shelf offering that the company plans to use for general corporate purposes.
According to the accompanying prospectus, general corporate purposes may include "working capital, capital expenditures, repayment and refinancing of debt, research and development expenditures, clinical trial expenditures, acquisitions of additional companies or technologies and investments."
Image Source: Getty Images.
Source: Fool.com
Agenus Inc. Stock
€0.41
-1.970%
Currently there is a rather positive sentiment for Agenus Inc. with 4 Buy predictions and 2 Sell predictions.
With a target price of 37 € there is potential for a 8841.52% increase which would mean more than doubling the current price of 0.41 € for Agenus Inc..
